Healthcare Industry News: sanofi-aventis
News Release - June 7, 2006
Cubist Pharmaceuticals Names William Pullman as Senior Vice President and Chief Medical OfficerLEXINGTON, Mass.--(HSMN NewsFeed)--June 7, 2006--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST ) today announced that William Pullman, M.D., Ph.D., has joined the company as Senior Vice President and Chief Medical Officer. Dr. Pullman will be a member of the company's Executive Team. In this new position, Dr. Pullman will oversee both clinical development and medical affairs.
Dr. Pullman has more than 25 years of medical experience. He practiced medicine and conducted doctoral and post-doctoral level research for more than 10 years at the beginning of his career. He then transitioned to the pharmaceutical industry, where he spent the last 14 years in a wide range of drug development positions. Most recently, he served as Senior Vice President, Exploratory Development at TransForm Pharmaceuticals, where he built and led the clinical group to support product development efforts.
Prior to TransForm, Dr. Pullman served as Senior Vice President, Clinical and Exploratory Pharmacology at sanofi-aventis, where he provided scientific leadership in the early clinical development phases. He also held numerous positions at Eli Lilly, most notably, serving as Medical Leader for the development and regulatory submission of Cialis. Dr. Pullman's industry experience began at Pfizer as a clinical pharmacologist. He is a fellow of the Royal Australian College of Physicians and received his Ph.D. in Immunology from the Australian National University.
"Dr. Pullman has proven success in leading drug development projects through all phases of the process," said Michael Bonney, President and CEO of Cubist. "He comes to Cubist at an exciting time for the company -- with the recent FDA approval of the expanded label for CUBICIN -- and I expect Bill to play a vital role in helping us build our acute care product pipeline leading to additional marketed products in the future."
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of antiinfective products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICINŽ (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our lipopeptide program, the product candidate HepeX-B(TM) and our natural products screening program. Cubist is headquartered in Lexington, MA. Additional information can be found at www.cubist.com.
Cubist Safe Harbor Statement
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and such statements are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cubist. These factors include, but are not limited to: (i) whether we will receive, and the potential timing and scope of, regulatory approvals or clearances to market CUBICIN in other countries and for additional indications in the United States and other countries pursuant to our currently-planned filings and any filings we determine to make in the future, which filings are subject to approval by the applicable regulatory agency or agencies, regardless of our confidence in the results of the clinical trials supporting such filings; (ii) the level of acceptance of CUBICIN by physicians, patients, and the medical community and the availability of reimbursement from third-party payors, including governments, private insurance plans and managed care providers; (iii) any changes in the current or anticipated market demand or medical need for CUBICIN; (iv) competition, particularly with respect to CUBICIN; (v) whether the FDA accepts proposed clinical trial protocols that may be achieved in a timely manner; (vi) our ability to conduct successful clinical trials in a timely manner; (vii) the ability of our third party manufacturers, including our single source provider of bulk drug substance, to manufacture sufficient quantities of CUBICIN in accordance with Good Manufacturing Practices and at an acceptable cost; (viii) our dependence upon pharmaceutical and biotechnology collaborations; (ix) our ability to finance our operations; (x) the effectiveness of our expanded sales force; (xi) potential costs resulting from product liability or other third party claims; (xii) our ability to protect our proprietary technologies; (xiii) our ability to discover, in-license, or acquire drug candidates and develop and achieve commercial success for drug candidates; (xiv) our ability to integrate successfully the operations of any business we may acquire and the potential impact of any future acquisition on our financial results; and (xv) a variety of risks common to our industry, including ongoing regulatory review, litigation relating to intellectual property, and legislative or regulatory changes.
Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cubist's recent filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in such filings.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.; HepeX-B is a trademark of XTL Biopharmaceuticals Ltd.
Source: Cubist Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.